Both medications can cause gastrointestinal side effects, which may be additive when used together
Consequently, GLP-1RAs may regulate EAT via multiple pathways, including suppression of local adipogenesis, increased fat utilization, and induction of white-to-brown adipocyte differentiation (95)
Epidemiological evidence suggests that sulfonylurea use is associated with an approximately 20% increased risk of specific malignancies, although the causality of this association requires further validation due to current evidence limitations [10]
This approach may favor multifactorial studies investigating the effects of BPC-157 alongside various: Growth factors Cytokines Extracellular matrix components BPC-157 may also feature in long-term studies
Engineered for Potency and Duration Discovered through Ascletis AI-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) , ASC35 combines extended half-life with high potency